首页> Lung cancer (Amsterdam, Netherlands)> Primary resistance to osimertinib due to SCLC transformation: Issue of T790M determination on liquid re-biopsy.

Primary resistance to osimertinib due to SCLC transformation: Issue of T790M determination on liquid re-biopsy.

导出 LinkOut

翻译打印收藏纠错

第一作者： R,Minari

第一单位： Medical Oncology Unit, University Hospital of Parma, Italy.

作者： R,Minari ^[1] ; P,Bordi ^[1] ; M,Del Re ^[2] ; F,Facchinetti ^[1] ; F,Mazzoni ^[3] ; F,Barbieri ^[4] ; A,Camerini ^[5] ; C E,Comin ^[6] ; L,Gnetti ^[7] ; C,Azzoni ^[7] ; R,Nizzoli ^[1] ; B,Bortesi ^[1] ; E,Rofi ^[2] ; P,Petreni ^[3] ; N,Campanini ^[7] ; G,Rossi ^[8] ; R,Danesi ^[2] ; M,Tiseo ^[9]

作者单位： Medical Oncology Unit, University Hospital of Parma, Italy. ^[1] Clinical Pharmacology and Pharmacogenetic Unit, Department of Clinical and Experimental Medicine, University of Pisa, Italy. ^[2] Department of Medical Oncology, Careggi Hospital of Firenze, Firenze, Italy. ^[3] Department of Oncology, University Hospital Policlinico of Modena, Modena, Italy. ^[4] Medical Oncology, Versilia Hospital, Lido di Camaiore, Italy. ^[5] Department of Experimental and Clinical Medicine, Section of Surgery, Histopathology and Molecular Pathology, University of Florence, Italy. ^[6] Pathology Unit, Department of Medicine and Surgery, University Hospital of Parma, Parma, Italy. ^[7] Pathology Unit, Azienda USL Valle d'Aosta, Regional Hospital "Parini", Aosta, Italy. ^[8] Medical Oncology Unit, University Hospital of Parma, Italy. Electronic address: mtiseo@ao.pr.it. ^[9]

关键词 EGFR Liquid biopsy NSCLC SCLC transformation T790M ddPCR